Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. insiders are currently net buyers of CRBP stock, showing bullish sentiment over the past 90 days. Executives have purchased $56.6M while selling $5.9M, resulting in a positive net flow of $50.7M. This buying activity represents 91% of total transaction volume.

Corbus Pharmaceuticals Holdings, Inc. has 23 active insiders who have filed SEC Form 4 transactions in the past 90 days. Bihua Chen (Executive) leads with 25 transactions totaling $32.8M. Asset Management, Lp Cormorant (Executive) follows with 1 transactions worth $14.3M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Corbus Pharmaceuticals Holdings, Inc.'s current score of 91/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $56.6M in purchases versus $5.9M in sales.

The most recent insider transaction occurred on Feb 3, 2026, when Hodgson Ian (Chief Operating Officer) disposed of 2,415 shares at $8.09 per share for $19.5K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, CRBP insider trading sentiment is currently bullish with an Alignment Score of 91/100. The net insider flow of $50.7M reflects accumulation, with 91% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Corbus Pharmaceuticals Holdings, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At CRBP, we track all Form 4 filings—currently showing 292 transactions from 23 insiders over 90 days.

A 10b5-1 plan allows Corbus Pharmaceuticals Holdings, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At CRBP, approximately 44% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor Corbus Pharmaceuticals Holdings, Inc. (CRBP) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 23 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Corbus Pharmaceuticals Holdings, Inc.'s current score of 91/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $56.6M in purchases versus $5.9M in sales over 90 days, resulting in a net flow of $50.7M.

SEC Form 4 filings are mandatory reports that Corbus Pharmaceuticals Holdings, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At CRBP, the most common type is "M" with 19 occurrences. The most recent Form 4 was filed on Feb 3, 2026 by Hodgson Ian.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Corbus Pharmaceuticals Holdings, Inc., approximately 44% of recent transactions are executed under 10b5-1 plans, while 56% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.